HUE052821T2 - 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása - Google Patents

7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása

Info

Publication number: HUE052821T2
Authority: HU; Hungary
Prior art keywords: benzyl; hexahydroimidazo; pyrido; pyrimidin; trifluoromethyl
Prior art date: 2015-01-30

Application number

HUE16744237A

Other languages

English (en)

Inventor

Martin Stogniew

Joshua E Allen

Richard S Pottorf

Bhaskara Rao Nallaganchu

Gary L Olson

Yanjun Sun

Original Assignee

Oncoceutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-30

Filing date

2016-01-29

Publication date

2021-05-28

2016-01-29 Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc

2021-05-28 Publication of HUE052821T2 publication Critical patent/HUE052821T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9413—Dopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Microbiology (AREA)

HUE16744237A 2015-01-30 2016-01-29 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása HUE052821T2 (hu)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201562109737P	2015-01-30	2015-01-30
US201562148844P	2015-04-17	2015-04-17
US201562233757P	2015-09-28	2015-09-28

Publications (1)

Publication Number	Publication Date
HUE052821T2 true HUE052821T2 (hu)	2021-05-28

Family

ID=56544438

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE16744237A HUE052821T2 (hu)	2015-01-30	2016-01-29	7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása

Country Status (26)

Country	Link
US (5)	US9845324B2 (hu)
EP (2)	EP3250208B1 (hu)
JP (2)	JP6802172B2 (hu)
KR (2)	KR20240005186A (hu)
CN (2)	CN107427516B8 (hu)
AU (4)	AU2016211243B2 (hu)
BR (1)	BR112017016487B1 (hu)
CA (3)	CA3209519A1 (hu)
CY (1)	CY1123616T1 (hu)
DK (1)	DK3250208T3 (hu)
EA (1)	EA037552B1 (hu)
ES (1)	ES2839401T3 (hu)
HR (1)	HRP20201949T1 (hu)
HU (1)	HUE052821T2 (hu)
IL (5)	IL312936A (hu)
LT (1)	LT3250208T (hu)
MA (2)	MA55402A (hu)
MD (1)	MD3250208T2 (hu)
MX (3)	MX2017009841A (hu)
NZ (2)	NZ772080A (hu)
PL (1)	PL3250208T3 (hu)
PT (1)	PT3250208T (hu)
RS (1)	RS61243B1 (hu)
SG (2)	SG11201706062TA (hu)
SI (1)	SI3250208T1 (hu)
WO (1)	WO2016123571A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA55402A (fr) *	2015-01-30	2022-02-02	Oncoceutics Inc	Dérivés de 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, leurs sels et leur utilisation en thérapie
CN104860948B (zh)	2015-05-15	2017-09-26	南京盖特医药技术有限公司	咪唑并嘧啶酮类化合物及其制备方法和应用
CA3013044A1 (en) *	2016-01-29	2017-08-03	Oncoceutics, Inc.	G protein-coupled receptor (gpcr) modulation by imipridones
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018031987A1 (en)	2016-08-12	2018-02-15	Nanjing Gator Meditech Company, Ltd.	Protein kinase regulators
WO2018169994A1 (en) *	2017-03-13	2018-09-20	City Of Hope	m6A mRNA MODIFICATION IN CANCER TREATMENT
EP3589745A1 (en) *	2018-04-11	2020-01-08	Chemestmed Ltd.	A method of modulating the rna methylation
CN113631192B (zh)	2019-03-26	2023-07-21	富士胶片株式会社	抑制乙型肝炎病毒蛋白产生的医药组合物、用于处置乙型肝炎的医药组合物及筛选方法
WO2021154750A1 (en) *	2020-01-29	2021-08-05	Corcept Therapeutics Incorporated	TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS
JP2023536524A (ja) *	2020-08-06	2023-08-25	エトヴェシュロラーンドトゥドマニュジェテム	新規イミプリドン誘導体の合成とその抗癌活性の評価
CN116249538A (zh)	2020-09-30	2023-06-09	富士胶片株式会社	抑制乙型肝炎病毒蛋白质的产生的双链rna及药物组合物
CN113100233B (zh) *	2021-04-19	2022-02-08	中国农业科学院植物保护研究所	芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用
CN115448921B (zh) *	2021-06-08	2023-08-01	四川大学	一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
WO2024218275A1 (en) *	2023-04-20	2024-10-24	Institut Gustave Roussy	Liquid and solid compositions of imipridone derivatives
CN117599041B (zh) *	2024-01-22	2024-05-03	中国人民解放军军事科学院军事医学研究院	去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2150062A1 (de) *	1971-10-07	1973-04-12	Boehringer Sohn Ingelheim	Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en)	1980-08-14	1987-02-10	Mead Johnson & Company	6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US4867973A (en)	1984-08-31	1989-09-19	Cytogen Corporation	Antibody-therapeutic agent conjugates
US4783450A (en)	1987-04-13	1988-11-08	Warner-Lambert Company	Use of commercial lecithin as skin penetration enhancer
US7635690B2 (en)	1999-01-22	2009-12-22	Emory University	HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7741285B2 (en)	2001-11-13	2010-06-22	Genentech, Inc.	APO-2 ligand/trail formulations
NZ535349A (en)	2002-03-08	2007-01-26	Signal Pharm Inc	JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
AU2003253186A1 (en) *	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en)	2003-03-17	2004-09-30	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005007871A2 (en)	2003-07-08	2005-01-27	The Regents Of The University Of California	Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof
DK2301531T3 (en)	2005-02-18	2018-07-30	Abraxis Bioscience Llc	COMBINATIONS AND WAYS FOR ADMINISTRATING THERAPEUTIC SUBSTANCES AND COMBINATION THERAPY
US20080221135A1 (en)	2005-05-13	2008-09-11	Bristol-Myers Squibb Company	Combination therapy
US8088895B2 (en)	2006-10-18	2012-01-03	Chemocentryx, Inc.	Antibodies that bind CXCR7 epitopes
EP2350641B1 (en)	2008-09-22	2014-09-24	Amgen Inc.	A combination of a tnf alpha inhibitor, an iap inhibitor and a trail receptor agonist for use in treating cancer
BRPI0922823A2 (pt)	2008-12-11	2015-08-18	Abraxis Bioscience Llc	Combinações e modos de administração de agentes terapêuticos e terapia de combinação
US9724337B2 (en)	2009-04-21	2017-08-08	University Of Kentucky Research Foundation	AG-205 for the treatment of breast cancer
WO2011144622A1 (en)	2010-05-17	2011-11-24	Boehringer Ingelheim International Gmbh	1h - imidazo [4, 5 - c] quinolines
US8735386B2 (en)	2010-07-23	2014-05-27	Boehringer Ingelheim International Gmbh	Aminopyrazoloquinazolines
AU2012240246A1 (en) *	2011-04-04	2013-05-09	Netherlands Cancer Institute	Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
US20130102595A1 (en) *	2011-04-15	2013-04-25	Curis, Inc.	Treatment of cancers having k-ras mutations
ES2786033T3 (es)	2011-04-29	2020-10-08	Penn State Res Found	Inducción del gen de TRAIL por moléculas pequeñas en células normales y tumorales como una terapia contra el cáncer
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EA037937B1 (ru) *	2013-03-13	2021-06-09	Онкосьютикс, Инк.	Способ получения дигидрохлоридной соли имидазо-пиридо-пиримидинона, фармацевтическая композиция на его основе и их применение для лечения рака
US9376437B2 (en) *	2013-03-13	2016-06-28	Oncoceutics, Inc	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) *	2013-11-15	2015-05-21	Oncoceutics, Inc.	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
AU2014349150B2 (en)	2013-11-15	2019-11-07	Oncoceutics, Inc.	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
EP3125898B1 (en) *	2014-03-31	2019-12-25	The Scripps Research Institute	Pharmacophore for trail induction
KR20150114239A (ko) *	2014-04-01	2015-10-12	제일모직주식회사	내열성 및 착색성이 향상된 열가소성 수지 조성물
MA55402A (fr)	2015-01-30	2022-02-02	Oncoceutics Inc	Dérivés de 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, leurs sels et leur utilisation en thérapie
CN104860948B (zh)	2015-05-15	2017-09-26	南京盖特医药技术有限公司	咪唑并嘧啶酮类化合物及其制备方法和应用

2016
- 2016-01-29 MA MA055402A patent/MA55402A/fr unknown
- 2016-01-29 ES ES16744237T patent/ES2839401T3/es active Active
- 2016-01-29 IL IL312936A patent/IL312936A/en unknown
- 2016-01-29 NZ NZ772080A patent/NZ772080A/en unknown
- 2016-01-29 WO PCT/US2016/015817 patent/WO2016123571A1/en active Application Filing
- 2016-01-29 HU HUE16744237A patent/HUE052821T2/hu unknown
- 2016-01-29 CA CA3209519A patent/CA3209519A1/en active Pending
- 2016-01-29 MA MA41434A patent/MA41434B1/fr unknown
- 2016-01-29 MX MX2017009841A patent/MX2017009841A/es unknown
- 2016-01-29 CN CN201680008476.7A patent/CN107427516B8/zh active Active
- 2016-01-29 SG SG11201706062TA patent/SG11201706062TA/en unknown
- 2016-01-29 AU AU2016211243A patent/AU2016211243B2/en active Active
- 2016-01-29 SI SI201631003T patent/SI3250208T1/sl unknown
- 2016-01-29 KR KR1020237044537A patent/KR20240005186A/ko active Search and Examination
- 2016-01-29 CA CA2975476A patent/CA2975476C/en active Active
- 2016-01-29 CA CA3209515A patent/CA3209515A1/en active Pending
- 2016-01-29 MD MDE20170317T patent/MD3250208T2/ro unknown
- 2016-01-29 EP EP16744237.5A patent/EP3250208B1/en active Active
- 2016-01-29 BR BR112017016487-6A patent/BR112017016487B1/pt active IP Right Grant
- 2016-01-29 IL IL288525A patent/IL288525B/en unknown
- 2016-01-29 MX MX2021001096A patent/MX2021001096A/es unknown
- 2016-01-29 LT LTEP16744237.5T patent/LT3250208T/lt unknown
- 2016-01-29 SG SG10201803508WA patent/SG10201803508WA/en unknown
- 2016-01-29 PT PT167442375T patent/PT3250208T/pt unknown
- 2016-01-29 IL IL295286A patent/IL295286B2/en unknown
- 2016-01-29 NZ NZ772369A patent/NZ772369A/en unknown
- 2016-01-29 RS RS20201566A patent/RS61243B1/sr unknown
- 2016-01-29 PL PL16744237T patent/PL3250208T3/pl unknown
- 2016-01-29 KR KR1020177022405A patent/KR102618971B1/ko active IP Right Grant
- 2016-01-29 EA EA201791727A patent/EA037552B1/ru unknown
- 2016-01-29 DK DK16744237.5T patent/DK3250208T3/da active
- 2016-01-29 JP JP2017540230A patent/JP6802172B2/ja active Active
- 2016-01-29 CN CN202110266214.3A patent/CN113149985A/zh active Pending
- 2016-01-29 EP EP20198062.0A patent/EP3805222A3/en active Pending
- 2016-02-22 US US15/049,613 patent/US9845324B2/en active Active
2017
- 2017-07-27 IL IL253689A patent/IL253689B/en active IP Right Grant
- 2017-07-28 MX MX2023000782A patent/MX2023000782A/es unknown
- 2017-11-20 US US15/817,896 patent/US10266533B2/en active Active
2019
- 2019-02-27 US US16/287,195 patent/US20190194201A1/en not_active Abandoned
2020
- 2020-04-22 IL IL274135A patent/IL274135B/en unknown
- 2020-11-26 JP JP2020195955A patent/JP7579684B2/ja active Active
- 2020-12-05 HR HRP20201949TT patent/HRP20201949T1/hr unknown
- 2020-12-07 AU AU2020286168A patent/AU2020286168B8/en active Active
- 2020-12-07 CY CY20201101158T patent/CY1123616T1/el unknown
2021
- 2021-06-24 US US17/357,008 patent/US11976068B2/en active Active
2022
- 2022-09-06 AU AU2022228096A patent/AU2022228096A1/en not_active Abandoned
2024
- 2024-03-12 US US18/603,075 patent/US20240270746A1/en active Pending
- 2024-05-22 AU AU2024203421A patent/AU2024203421A1/en active Pending

Also Published As

Publication number	Publication date
MA41434B1 (fr)	2021-03-31
ES2839401T3 (es)	2021-07-05
AU2020286168B8 (en)	2022-09-22
CN107427516B8 (zh)	2021-04-09
BR112017016487B1 (pt)	2023-11-07
US20180072729A1 (en)	2018-03-15
CA3209515A1 (en)	2016-08-04
EP3250208B1 (en)	2020-09-30
EP3805222A2 (en)	2021-04-14
CY1123616T1 (el)	2022-03-24
US20220017519A1 (en)	2022-01-20
JP6802172B2 (ja)	2020-12-16
IL295286B2 (en)	2024-10-01
EA201791727A1 (ru)	2018-01-31
IL253689B (en)	2020-05-31
KR20240005186A (ko)	2024-01-11
RS61243B1 (sr)	2021-01-29
WO2016123571A1 (en)	2016-08-04
CA3209519A1 (en)	2016-08-04
IL288525B (en)	2022-09-01
NZ772369A (en)	2024-07-05
NZ772080A (en)	2024-07-05
PT3250208T (pt)	2021-01-06
MA55402A (fr)	2022-02-02
EP3805222A3 (en)	2021-06-30
DK3250208T3 (da)	2021-01-04
CN107427516B (zh)	2021-02-26
EP3250208A4 (en)	2018-10-03
MX2023000782A (es)	2023-02-14
IL295286B1 (en)	2024-06-01
US9845324B2 (en)	2017-12-19
EA037552B1 (ru)	2021-04-13
KR20170109583A (ko)	2017-09-29
SG11201706062TA (en)	2017-08-30
IL312936A (en)	2024-07-01
MX2017009841A (es)	2018-02-09
IL274135A (en)	2020-06-30
KR102618971B1 (ko)	2023-12-27
IL274135B (en)	2022-01-01
JP2021050209A (ja)	2021-04-01
AU2020286168B2 (en)	2022-06-09
IL295286A (en)	2022-10-01
US20190194201A1 (en)	2019-06-27
AU2022228096A1 (en)	2022-09-29
HRP20201949T1 (hr)	2021-01-22
US10266533B2 (en)	2019-04-23
MA41434A (fr)	2017-12-06
CA2975476C (en)	2023-10-03
IL288525A (en)	2022-01-01
AU2020286168A1 (en)	2021-01-07
MD3250208T2 (ro)	2021-02-28
JP7579684B2 (ja)	2024-11-08
AU2024203421A1 (en)	2024-06-13
SI3250208T1 (sl)	2021-01-29
JP2018503663A (ja)	2018-02-08
BR112017016487A2 (pt)	2018-04-10
US20240270746A1 (en)	2024-08-15
NZ733994A (en)	2024-04-26
EP3250208A1 (en)	2017-12-06
CA2975476A1 (en)	2016-08-04
AU2016211243B2 (en)	2020-09-10
SG10201803508WA (en)	2018-05-30
IL253689A0 (en)	2017-09-28
US20170096431A1 (en)	2017-04-06
CN113149985A (zh)	2021-07-23
US11976068B2 (en)	2024-05-07
LT3250208T (lt)	2021-01-25
CN107427516A (zh)	2017-12-01
PL3250208T3 (pl)	2021-04-06
MX2021001096A (es)	2023-01-17
AU2016211243A1 (en)	2017-08-10

Publication	Publication Date	Title
RS61243B1 (sr)	2021-01-29	7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2 a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primena u terapiji
IL262698B (en)	2022-04-01	[1,2-b]Amidazo-converted pyridazines, [1,5-b]imidazo-converted pyridazines, related compounds and their use for the treatment of medical disorders
IL288674A (en)	2022-02-01	7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidine-5(1h)one, its salts and methods Use
LT3215511T (lt)	2024-06-25	Pakeistieji pirazolo(1,5-a)pirimidinai ir jų panaudojimas medicininių sutrikimų gydymui
EP3215509A4 (en)	2018-03-14	Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
EP3215510A4 (en)	2018-04-11	Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
IL251107B (en)	2022-05-01	History of [2h]-imidazo-[1,2-a]pyrazolo[3,4-e]pyrimidine-4(5h)-one, pharmaceutical preparations containing them and their use in disorders of the central nervous system.
EP3344625A4 (en)	2019-03-27	THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE